Langerhans cell histiocytosis
Conditions
Interventions
Experimental group:Based on an accurate risk stratification system including the levels of plasma cfBRAF-V600E, LCH patients were treated by the first-line therapy (Prednisone, Vindesine), the second-
Control group:According to the conventional evaluation system of involved organs, LCH patients were treated by the first-line therapy, the second-line therapy and the maintenance therapy.
Sponsors
Beijing Children's Hospital, Capital Medical University, National Children's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: (1) Patients were diagnosed as LCH by clinical and pathological examination in our hospital; (2) Patients aged less than 18 years; (3) Informed consent were obtained from guardians of the patients and the patients (more than 8 years old).
Exclusion criteria
Exclusion criteria: (1) Patient who had received any anti-tumor treatment before diagnosis; (2) Patient who was allergic to any drug included in this study; (3) Patients who can't perform the treatment according to the standardized protocol of this study; (4) Patient who was unable to comply during the trial and / or follow-up phase.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free Survival;Event-free survival;Cumulative incidence of relapse;Response rate;Efficacy index for judging prognosis by a new type of risk stratification system; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of permanent consequences;Negative conversion rate of cfBRAF-V600E in plasma;Hazard ratio;Overall survival;Tissue BRAF mutations;Dynamic changes of key biomarkers during treatment; | — |
Countries
China
Contacts
Public ContactRui Zhang
Beijing Children's Hospital, Capital Medical University, National Children's Medical Center
Outcome results
None listed